Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 268

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 268
---
 of the warrants and exercise
price were adjusted retroactively to reflect the Split, see Note 1c.

<div align='center'>F-18</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT LIABILITY (Cont.) |

The warrants represent a freestanding
instrument accounted for at fair value and re-measured at each reporting date. The Company estimates the fair value of the warrants using
PWERM. A summary of significant unobservable inputs (Level 3 inputs) used in measuring the fair value of the warrants issued are as follows:

|                    |     |   | December 31, 
         2024 |   |     |   | December 31, 
         2023 |   |
|:-------------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Number of warrants |     |   |      167,365 |   |     |   |      167,365 |   |
| Discount rate      |     |   |         30.0 | % |     |   |         30.0 | % |
| Term (years)       |     |   |         0.25 |   |     |   |         0.25 |   |
| Fair value         |     | $ |          160 |   |     | $ |          221 |   |

The following table presents changes
in the fair value of the warrant liability:

| Balance as of January 1, 2023   |     | $ | 278 |   |
| Changes in fair value           |     |   | (57 | ) |
| Balance as of December 31, 2023 |     | $ | 221 |   |
| Changes in fair value           |     |   | (61 | ) |
| Balance as of December 31, 2024 |     | $ | 160 |   |

The Company has performed a sensitivity
analysis of the warrant liability which is classified as level 3 financial instruments. The Company recalculated the value of the warrants
by applying a +/- 5.0% changes to the input variables in PWERM. As of December 31, 2024, a 5.0% decrease in discount rate would increase
the fair value of the warrants to $164